PMID- 26284297
OWN - NLM
STAT- MEDLINE
DCOM- 20160503
LR  - 20180913
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Linking)
VI  - 21
IP  - 9
DP  - 2015 Sep
TI  - The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha 
      Agents in Children and Adolescents with Inflammatory Bowel Disease.
PG  - 2214-21
LID - 10.1097/MIB.0000000000000420 [doi]
AB  - BACKGROUND: Anti-tumor necrosis factor alpha (TNFalpha) therapy is effective in 
      pediatric patients with inflammatory bowel disease (IBD) but associated with a 
      risk of developing anti-drug antibodies (ADA) which lower the efficacy. 
      Incorporating measurement of trough levels and ADA (therapeutic drug monitoring) 
      may prevent the development of neutralizing ADA or could contribute to more 
      optimal treatment strategies if ADA are already formed. The aim of this review 
      was to investigate the role of therapeutic drug monitoring in children and 
      adolescents with IBD exposed to anti-TNFalpha agents. METHODS: A literature search 
      identified publications that measured anti-TNFalpha drug trough levels and/or ADA in 
      children or adolescents with IBD. Studies were eligible when (1) article was 
      written in English, (2) original data were available, (3) full text article or 
      abstract was available, (4) measurement of antibodies against anti-TNFalpha drugs or 
      trough level of anti-TNFalpha drugs were reported, and (5) levels were measured in 
      pediatric patients with IBD. RESULTS: The search yielded 811 articles, of which 
      795 articles were excluded based on title or abstract. A total of 14 studies were 
      included in the review. CONCLUSIONS: Therapeutic drug monitoring within the 
      pediatric IBD population certainly has a potential benefit. As occurrence of 
      immune reactions to anti-TNFalpha agents varies widely, incorporating measurement of 
      IFX trough levels at week 8 or week 14 predicts therapy response and allows for 
      dose adjustments to reach therapeutic drug concentrations. However, a clinically 
      relevant cutoff level for ADA has not been defined yet, and the optimal 
      intervention strategy still has to be determined.
FAU - Joosse, Maria E
AU  - Joosse ME
AD  - *Department of Pediatrics, Laboratory of Pediatrics, Division of Gastroenterology 
      and Nutrition, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The 
      Netherlands; daggerDepartment of Gastroenterology and Hepatology, Erasmus Medical 
      Center-Sophia Children's Hospital, Rotterdam, The Netherlands; and double daggerDepartment of 
      Hospital Pharmacy, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, 
      The Netherlands.
FAU - Samsom, Janneke N
AU  - Samsom JN
FAU - van der Woude, C Janneke
AU  - van der Woude CJ
FAU - Escher, Johanna C
AU  - Escher JC
FAU - van Gelder, Teun
AU  - van Gelder T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - 0 (Antibodies)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Antibodies/blood
MH  - Child
MH  - *Drug Monitoring
MH  - *Drug Tolerance
MH  - Humans
MH  - Inflammatory Bowel Diseases/blood/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/blood/therapeutic use
EDAT- 2015/08/19 06:00
MHDA- 2016/05/04 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/05/04 06:00 [medline]
AID - 00054725-201509000-00023 [pii]
AID - 10.1097/MIB.0000000000000420 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2015 Sep;21(9):2214-21. doi: 10.1097/MIB.0000000000000420.